Xie F - Search Results

1

Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.

Kiflen M, Le A, Mao S, Lali R, Narula S, Xie F, Paré G. Kiflen M, et al. Among authors: xie f. Circ Genom Precis Med. 2022 Oct;15(5):e003423. doi: 10.1161/CIRCGEN.121.003423. Epub 2022 Jul 29. Circ Genom Precis Med. 2022. PMID: 35904973

2

Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese.

Xie F, Luo N, Blackhouse G, Goeree R, Lee HP. Xie F, et al. Int J Technol Assess Health Care. 2008 Winter;24(1):87-95. doi: 10.1017/S0266462307080117. Int J Technol Assess Health Care. 2008. PMID: 18218173

3

Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers.

Shortt C, Xie F, Whitlock R, Ma J, Clayton N, Sherbino J, Hill SA, Pare G, McQueen M, Mehta SR, Devereaux PJ, Worster A, Kavsak P. Shortt C, et al. Among authors: xie f. Clin Chem. 2017 Feb;63(2):593-602. doi: 10.1373/clinchem.2016.261776. Epub 2016 Nov 3. Clin Chem. 2017. PMID: 27811206 Clinical Trial.

4

Who Benefits Most from Collaborative Dementia Care from a Patient and Payer Perspective? A Subgroup Cost-Effectiveness Analysis.

Rädke A, Michalowsky B, Thyrian JR, Eichler T, Xie F, Hoffmann W. Rädke A, et al. Among authors: xie f. J Alzheimers Dis. 2020;74(2):449-462. doi: 10.3233/JAD-190578. J Alzheimers Dis. 2020. PMID: 32039839

5

Health-Related Quality-of-Life and Cost Utility Analyses in Critical Care: A Systematic Review.

Lau VI, Xie F, Basmaji J, Cook DJ, Fowler R, Kiflen M, Sirotich E, Iansavichene A, Bagshaw SM, Wilcox ME, Lamontagne F, Ferguson N, Rochwerg B. Lau VI, et al. Among authors: xie f. Crit Care Med. 2021 Apr 1;49(4):575-588. doi: 10.1097/CCM.0000000000004851. Crit Care Med. 2021. PMID: 33591013

6

Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.

Zhou T, Chen Z, Li H, Xie F. Zhou T, et al. Among authors: xie f. Med Decis Making. 2021 Aug;41(6):685-692. doi: 10.1177/0272989X211004532. Epub 2021 Apr 3. Med Decis Making. 2021. PMID: 33813938 Free PMC article.

7

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia.

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F. Kaur MN, et al. Among authors: xie f. Blood Adv. 2022 Feb 8;6(3):785-792. doi: 10.1182/bloodadvances.2021005627. Blood Adv. 2022. PMID: 34781363 Free PMC article.

8

A Systematic Literature Review of Health Utility Values in Breast Cancer.

Kaur MN, Yan J, Klassen AF, David JP, Pieris D, Sharma M, Bordeleau L, Xie F. Kaur MN, et al. Among authors: xie f. Med Decis Making. 2022 Jul;42(5):704-719. doi: 10.1177/0272989X211065471. Epub 2022 Jan 18. Med Decis Making. 2022. PMID: 35042379 Free PMC article.

9

Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).

Donovan EK, Xie F, Louie AV, Chu W, Siva S, Kapoor A, Swaminath A. Donovan EK, et al. Among authors: xie f. Clin Genitourin Cancer. 2022 Oct;20(5):e353-e361. doi: 10.1016/j.clgc.2022.03.011. Epub 2022 Mar 28. Clin Genitourin Cancer. 2022. PMID: 35490099

10

Industry sponsorship bias in cost effectiveness analysis: registry based analysis.

Xie F, Zhou T. Xie F, et al. BMJ. 2022 Jun 22;377:e069573. doi: 10.1136/bmj-2021-069573. BMJ. 2022. PMID: 35732297 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,451 results

Search Page

Filters